NanoViricides, Inc. (OTC BB: NNVC) (the "Company") reports that post-infection treatment with its oral FluCide™ drug candidate achieved dramatic reduction in the levels of infectious virus in the lungs of animals with a lethal H3N2 influenza virus infection. These findings corroborate the recently reported findings of increased animal survival in oral FluCide-treated animals infected with H3N2 influenza A. These findings also indicate that oral FluCide is at least ten-times superior to oral oseltamivir (Tamiflu®), when comparing lung viral load and protection of lungs from damage caused by the influenza pathology.
Four days after virus infection, the infectious viral load in lungs of infected animals treated with the best oral FluCide™ nanoviricide drug candidate was reduced greater than 30-fold as compared to the infected, untreated control animals, at day 4. In contrast, animals treated with Oseltamivir (Tamiflu®) showed only an approximate 3-fold reduction in lung viral load at day 4. At 7 days, the viral load in the lungs of Oseltamivir-treated animals was increased to the same level as that found in the infected, untreated control animals shortly before their death, while the lung viral load at 7 days in the FluCide-treated animals remained at the same 30-fold reduction. Thus, this oral FluCide appeared to be at least 10x more effective than oral Oseltamivir.
Of clinical significance, the reduction in lung viral load achieved by oral FluCide treatment with this drug candidate was accompanied by a correspondingly dramatic protection of the lungs from damage. Lung damage pathology is caused by both (i) influenza virus infection and expansion, and (ii) the body’s immune response to fight the infection. Microscopic evaluation of the lung tissues from FluCide-treated animals at day 4 showed an approximate 100-fold reduction in virus-induced inflammation and necrosis as compared to infected, untreated control animals. In contrast, at day 4, the lungs of Oseltamivir-treated animals showed only a 2-fold reduction.
The Company has previously reported that the same oral FluCide™ nanoviricide drug candidate achieved significantly increased survival of 15-16 days while animals treated with oral Oseltamivir survived only 9-10 days.
The current study provides further support for the potential of a therapeutic nanoviricide to protect against multiple influenza virus sub-types. Such broad-spectrum anti-influenza activity is highly sought after for a drug to be effective in seasonal influenza epidemics. Influenza viruses often change from season to season. In addition, severe epidemics or pandemics may be caused by a novel strain of influenza that emerges from time to time.
The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One hundred thousand virus particles of Influenza A Strain A/W/67 (H3N2v) were aspirated directly into the lungs of mice. The same quantity of virus infection was repeated at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with both FluCide candidates and Tamiflu® (Roche) commenced 24 hours after the first viral infection.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.Business Wire
Last updated on: 09/10/2012